Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Review

Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes

Authors: Shing Cheng Tan, Ravindran Ankathil

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Cervical cancer is a common malignancy which poses a significant health burden among women, especially those living in the developing countries. Although human papillomavirus (HPV) infection has been unequivocally implicated in the etiopathogenesis of the cancer, it alone is not adequate to contribute to the malignant transformation of cervical cells. Most HPV infections regress spontaneously, and only a small proportion of women have persistent infections which eventually lead to malignancy. This suggests that interplays between HPV infection and other cofactors certainly exist during the process of cervical carcinogenesis, which synergistically contribute to the differential susceptibility of an individual to the malignancy. Undoubtedly, host genetic factors represent a major element involved in such a synergistic interaction, and accumulating evidence suggests that polymorphisms in apoptosis-related genes play an important role in the genetic susceptibility to cervical cancer. This review consolidates the recent literatures on the role of common polymorphisms in apoptosis-related genes in genetic susceptibility to cervical cancer.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer: Lyon, France; 2013. Available from: http://​globocan.​iarc.​fr.
2.
Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5(6), e132.PubMedPubMedCentralCrossRef
3.
Othman NH, Devi BC, Halimah Y. Cervical cancer screening: patients understanding in major hospitals in Malaysia. Asian Pac J Cancer Prev. 2009;10(4):569–74.PubMed
4.
Boyle P, Levin B. World cancer report. Lyon, France: IARC Press; 2008.
5.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMedCrossRef
6.
7.
de Freitas AC, Coimbra EC, Leitão MC. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta. 2014;1845(2):91–103.PubMed
8.
White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A. 2012;109(5):E260–7.PubMedPubMedCentralCrossRef
9.
Zhang X, Zhang L, Tian C, Yang L, Wang Z. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. BJOG. 2014;121(6):664–74.PubMedCrossRef
10.
Liu P, Xu L, Sun Y, Wang Z. The association between cytotoxic T lymphocyte-associated antigen-4 and cervical cancer. Tumour Biol. 2014;35(4):2893–903.PubMedCrossRef
11.
Li Y, Liu F, Tan SQ, Wang Y, Li SW. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS ONE. 2012;7(9), e44441.PubMedPubMedCentralCrossRef
12.
Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, et al. The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis. Tumour Biol. 2014;35(2):903–16.PubMedCrossRef
13.
Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10–819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS. 2013;17(4):200–14.PubMedPubMedCentralCrossRef
14.
15.
Khan KH, Blanco-Codesido M, Molife LR. Cancer therapeutics: targeting the apoptotic pathway. Crit Rev Oncol Hematol. 2014;90(3):200–19.PubMedCrossRef
16.
Assoumou SZ, Boumba AL, Ndjoyi-Mbiguino A, Khattabi A, Ennaji MM. The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. Med Oncol. 2015;32(1):281.PubMedCrossRef
17.
Roh JW, Kim BK, Lee CH, Kim J, Chung HH, Kim JW, et al. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res. 2010;18(9):453–9.PubMedCrossRef
18.
Vargas-Torres SL, Portari EA, Klumb EM, Guillobel HC, Camargo MJ, Russomano FB, et al. Effects of MDM2 promoter polymorphisms on the development of cervical neoplasia in a Southeastern Brazilian population. Biomarkers. 2014;19(8):637–45.PubMedCrossRef
19.
Ndiaye R, Dem A, Mbaye PM, Guèye PM, Diop G, Diop PA, et al. Study of codon 72 of p53 gene as a risk-factor in cervical cancer in Senegal. Bull Cancer. 2014;101(9):789–94.PubMed
20.
Laprano TD, Lemos EH, Cunha LM, Júnior JE, de SousaTeles RA, Rabenhorst SH. Association of TP53 codon 72 and intron 3 16-bp Ins/Del polymorphisms with cervical cancer risk. Tumour Biol. 2014;35(8):7435–40.PubMedCrossRef
21.
Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1–10.
22.
Da Ros CT, Schmitt CS. Global epidemiology of sexually transmitted diseases. Asian J Androl. 2008;10(1):110–4.PubMedCrossRef
23.
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.PubMedCrossRef
24.
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204.PubMedCrossRef
25.
Nguyen HP, Ramírez-Fort MK, Rady PL. The biology of human papillomaviruses. Curr Probl Dermatol. 2014;45:19–32.PubMedCrossRef
26.
Mistry N, Simonsson M, Evander M. Transcriptional activation of the human papillomavirus type 5 and 16 long control region in cells from cutaneous and mucosal origin. Virol J. 2007;4:27.PubMedPubMedCentralCrossRef
27.
28.
29.
30.
Wang J, Sampath A, Raychaudhuri P, Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene. 2001;20(34):4740–9.PubMedCrossRef
31.
Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Bodén E, et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis. 1995;22(2):119–27.PubMedCrossRef
32.
Castellsagué X, Bosch FX, Muñoz N. The male role in cervical cancer. Salud Publica Mex. 2003;45 Suppl 3:S345–53.PubMedCrossRef
33.
Lam JU, Rebolj M, Dugué PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of human papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21(1):38–50.PubMedCrossRef
34.
Lee H, Lee DH, Song YM, Lee K, Sung J, Ko G. Risk factors associated with human papillomavirus infection status in a Korean cohort. Epidemiol Infect. 2014;142(8):1579–89.PubMedCrossRef
35.
Albero G, Castellsagué X, Giuliano AR, Bosch FX. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis. 2012;39(2):104–13.PubMedCrossRef
36.
Plummer M, Peto J, Franceschi S. International Collaboration of Epidemiological Studies of Cervical Cancer. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer. 2012;130(11):2638–44.PubMedCrossRef
37.
Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer. 2005;92(5):891–4.PubMedPubMedCentralCrossRef
38.
Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol. 2000;96(3):403–9.PubMed
39.
Moktar A, Singh R, Vadhanam MV, Ravoori S, Lillard JW, Gairola CG, et al. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int J Oncol. 2011;39(4):941–7.PubMedPubMedCentral
40.
Haverkos HW, Soon G, Steckley SL, Pickworth W. Cigarette smoking and cervical cancer: part I: a meta-analysis. Biomed Pharmacother. 2003;57(2):67–77.PubMedCrossRef
41.
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–95.CrossRef
42.
Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–50.PubMedCrossRef
43.
Paramita S, Soewarto S, Widodo MA, Sumitro SB. High parity and hormonal contraception use as risk factors for cervical cancer in East Kalimantan. Med J Indones. 2010;19:268–72.CrossRef
44.
45.
de Sanjosé S, Bosch FX, Muñoz N, Shah K. Social differences in sexual behaviour and cervical cancer. IARC Sci Publ. 1997;138:309–17.
46.
Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553–60.PubMedPubMedCentralCrossRef
47.
Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1413–4.PubMedCrossRef
48.
Ahlbom A, Lichtenstein P, Malmström H, Feychting M, Hemminki K, Pedersen NL. Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst. 1997;89(4):287–93.PubMedCrossRef
49.
Vink JM, van Kemenade FJ, Meijer CJ, Casparie MK, Meijer GA, Boomsma DI. Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters. Eur J Hum Genet. 2011;19(1):108–11.PubMedCrossRef
50.
Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer. 1999;82(6):775–81.PubMedCrossRef
51.
Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011;19(1):33–9.PubMedCrossRef
52.
Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene. 2004;23(38):6471–6.PubMedCrossRef
53.
Tan SC, Suzairi MS, Aizat AA, Aminudin MM, Nurfatimah MS, Bhavaraju VM, et al. Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer. Med Oncol. 2013;30(4):693.PubMedCrossRef
54.
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–41.PubMedCrossRef
55.
Bender T, Martinou JC. Where killers meet—permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol. 2013;5(1):a011106.PubMedPubMedCentralCrossRef
56.
Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 2011;351(1–2):41–58.PubMedCrossRef
57.
Hu Q, Wu D, Chen W, Yan Z, Yan C, He T, et al. Molecular determinants of caspase-9 activation by the Apaf-1 apoptosome. Proc Natl Acad Sci U S A. 2014;111(46):16254–61.PubMedPubMedCentralCrossRef
58.
Vaux DL. Apoptogenic factors released from mitochondria. Biochim Biophys Acta. 2011;1813(4):546–50.PubMedCrossRef
59.
Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87(1):99–163.PubMedCrossRef
60.
LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27(48):6252–75.PubMedCrossRef
61.
Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol. 2002;12(4):309–15.PubMedCrossRef
62.
63.
Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55(3):178–94.PubMedCrossRef
64.
65.
66.
67.
Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2000;21:2283–94.CrossRef
68.
Bai L, Zhu WG. p53: structure, function and therapeutic applications. J Cancer Mol. 2006;2(4):141–53.
69.
Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55(19):4438–45.PubMed
70.
Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002;21(57):8843–51.PubMedCrossRef
71.
Yuan CH, Filippova M, Duerksen-Hughes P. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses. 2012;4:3831–50.PubMedPubMedCentralCrossRef
72.
Cai Q, Lv L, Shao Q, Li X, Dian A. Human papillomavirus early proteins and apoptosis. Arch Gynecol Obstet. 2013;287:541–8.PubMedCrossRef
73.
Jiang P, Yue Y. Human papillomavirus oncoproteins and apoptosis (review). Exp Ther Med. 2014;7(1):3–7.PubMed
74.
Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29(6):1183–8.PubMed
75.
Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327–30.PubMed
76.
Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003;103(2):221–5.PubMedCrossRef
77.
Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99(1):113–8.PubMedCrossRef
78.
Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Fas gene promoter −670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006;16 Suppl 1:179–82.PubMedCrossRef
79.
Kordi Tamandani DM, Sobti RC, Shekari M. Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 2008;35(3):183–6.PubMed
80.
Shen J, Sun NX. Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis. Tumour Biol. 2013;34(6):3443–8.PubMedCrossRef
81.
Zhang Y, Tong S, Guan L, Na F, Zhao W, Wei L. CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35(3):1785–90.PubMedCrossRef
82.
Chen X, Mo W, Peng Q, Su X. Lack of association between Fas rs180082 polymorphism and risk of cervical cancer: an update by meta-analysis. BMC Med Genet. 2013;14:71.PubMedPubMedCentralCrossRef
83.
Qiu LX, Shi J, Yuan H, Jiang X, Xue K, Pan HF, et al. FAS −1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet. 2009;125(4):431–5.PubMedCrossRef
84.
Zhong-Xing Z, Yuan-Yuan M, Hai Zhen M, Jian-Gang Z, Li-Feng Z. FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls. PLoS ONE. 2013;8(8), e73700.PubMedPubMedCentralCrossRef
85.
Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.PubMedPubMedCentralCrossRef
86.
Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, et al. Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009;31(1):38–41.PubMed
87.
Kang S, Dong SM, Seo SS, Kim JW, Park SY. FAS −1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180(1):1–5.PubMedCrossRef
88.
Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202(7):967–74.PubMedPubMedCentralCrossRef
89.
Wang GQ, Bao L, Zhao XX, Zhang J, Nan KJ. Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis. Tumour Biol. 2014;35(5):4107–12.PubMedCrossRef
90.
Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181(1):71–7.PubMedCrossRef
91.
Lerma E, Romero M, Gallardo A, Pons C, Muñoz J, Fuentes J, et al. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch. 2008;452(1):65–74.PubMedCrossRef
92.
Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–8.PubMedCrossRef
93.
Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer. 2007;121(11):2451–7.PubMedCrossRef
94.
Zhu J, Lu L, Cheng X, Xie R, Chen Z, Li Y, et al. Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35(6):5137–42.PubMedCrossRef
95.
Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. The p53 circuit board. Biochim Biophys Acta. 2012;1825(2):229–44.PubMedPubMedCentral
96.
97.
Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001;3(6):552–8.PubMedCrossRef
98.
Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001;61(18):6660–4.PubMed
99.
Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis—the p53 network. J Cell Sci. 2003;116(Pt 20):4077–85.PubMedCrossRef
100.
Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998;282(5387):290–3.PubMedCrossRef
101.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393(6682):229–34.PubMedCrossRef
102.
Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S, Trikalinos TA. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol. 2013;177(12):1317–25.PubMedPubMedCentralCrossRef
103.
Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10(8):772–84.PubMedCrossRef
104.
Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, et al. p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18(23):6407–15.PubMedCrossRef
105.
Zhou X, Gu Y, Zhang SL. Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012;13(10):4909–14.PubMedCrossRef
106.
Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21(5):553–74.PubMedCrossRef
107.
108.
Shi D, Gu W. Dual roles of MDM2 in the regulation of p53: ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 2012;3(3–4):240–8.PubMedPubMedCentralCrossRef
109.
Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol. 2011;12(7):439–52.PubMedCrossRef
110.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.PubMedCrossRef
111.
Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32(1):19–27.PubMedCrossRef
112.
Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecol Oncol. 2010;118(3):258–61.PubMedCrossRef
113.
Jiang P, Liu J, Li W, Zeng X, Tang J. Correlation between MDM2 gene SNP 309 polymorphisms and cervical cancer. Chin J Clin Oncol. 2011;1:1–4.
114.
Meissner Rde V, Barbosa RN, Fernandes JV, Galvão TM, Galvão AF, Oliveira GH. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev. 2007;31(5):371–4.PubMedCrossRef
115.
Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, et al. TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(3):755–61.PubMedPubMedCentralCrossRef
116.
Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49–54.PubMedCrossRef
117.
Zhuo X, Ren J, Li D, Wu Y, Zhou Q. MDM2 SNP309 variation increases cervical cancer risk among Asians. Tumour Biol. 2014;35(6):5331–7.PubMedCrossRef
118.
Piccolo MT, Crispi S. The dual role played by p21 may influence the anti-apoptotic fate in cancer. J Cancer Res Updates. 2012;1:189–202.
119.
Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1(8):639–49.PubMed
120.
Dong C, Li Q, Lyu SC, Krensky AM, Clayberger C. A novel apoptosis pathway activated by the carboxyl terminus of p21. Blood. 2005;105(3):1187–94.PubMedCrossRef
121.
Tian Q, Lu W, Chen H, Ye F, Xie X. The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. Int J Gynecol Cancer. 2009;19(6):1011–4.PubMedCrossRef
122.
Wang N, Wang S, Zhang Q, Lu Y, Wei H, Li W, et al. Association of p21 SNPs and risk of cervical cancer among Chinese women. BMC Cancer. 2012;11(12):589.CrossRef
123.
Jiang P, Liu J, Li W, Zeng X, Tang J. Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women. Acta Biochim Biophys Sin. 2010;42(9):671–6.PubMedCrossRef
124.
Li Y, Liu F, Tan S, Li S. P21 Ser31Arg polymorphism and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2011;21(3):445–51.PubMedCrossRef
125.
Ma Y, Zhang Y, Lin L, Guo X, Wu Y, Wen W, et al. Quantitative assessment of the relationship between p21 Ser31Arg polymorphism and cervical cancer. Tumour Biol. 2013;34(6):3887–92.PubMedCrossRef
126.
Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39(5):605–13.PubMedCrossRef
127.
Chatterjee K, Williamson AL, Hoffman M, Dandara C. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer. J Med Virol. 2011;83(4):630–6.PubMedCrossRef
Metadata
Title
Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes
Authors
Shing Cheng Tan
Ravindran Ankathil
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3868-2

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Research Article

Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma

Retraction Note

Retraction Note to: Identification of core miRNA based on small RNA-seq and RNA-seq for colorectal cancer by bioinformatics

Research Article

Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients

Research Article

MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK

Research Article

Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer

Research Article

Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits